- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03473496
CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma (MM)
The Prospective, Multi-center And Single-arm Clinical Study of Chimeric Antigen Receptor T(CAR-T) Cells Therapy in Relapsed/Refractory Multiple Myeloma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Multiple myeloma(MM) is one of the most common malignant diseases in the blood system.There is still no cure for the disease which only control the development of the disease in various ways.
In recent years, the understanding of pathogenic molecular mechanism in MM , many new types of drugs can be used in the treatment of this disease, one of the most widely used is proteasome inhibitors and immune regulator.Hematopoietic stem cell transplantation has also been shown to improve complete remission rates and prolong patient survival.Combined with the advantages of multiple therapies, chimeric antigen receptor T cells (CAR-T) have gradually become one of the strongest and most powerful weapons against multiple myeloma.
CAR - T cells was taken in the form of genetic modification, and specific identified target antigen monoclonal antibody of single variable region (scFv) expression in T cell surface, and coupled with the activation of intracellular proliferation signal domain.
When scFv recognizes antigens expressed in malignant cells, it stimulates the activation signal of downstream T cells and produces specific killing effects. CAR-T therapy is one of revolutionary targeted immunotherapy.The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, and several clinical trials have been reported in the treatment of multiple myeloma with CAR-T cells.Throughout registration of clinical trials and published research results, B-cell maturation antigen (BCMA) as one of targets , its effect is more significant than other molecules.As with BCMA antigens, cluster of differentiation 138(CD138), cluster of differentiation 56 (CD56) or cluster of differentiation 38(CD38) antigens are also highly expressed in multiple myeloma cells.With CD138 as the target for the treatment of CAR-T cells, several clinical studies have been registered, and the results show that some of them are effective.
In order to lay a foundation for the application of relapsed/refractory multiple myeloma patients with CAR-T therapy,objects are refractory/ relapsed patients with multiple myeloma,and plans to into the group of the number of cases in 50 cases.The main content is safety, efficacy and feasibility analysis of the CAR-T cells (single CAR-T or double CAR-T cells with BCMA、CD138、CD56 or CD38 ) in the treatment of refractory/relapsed multiple myeloma.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangdong, Guangdong, China, 510000
- Southern Medical University Zhujiang Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Relapsed/Refractory MM patients
- Cell phenotype is BCMA/CD138/CD38/CD56 positive (single or combined) ,and minimal residual disease (MRD) was positive(cytology, genetic testing)
- Estimated survival time is more than 3 months in multiple myeloma,and Karnofsky performance status(KPS) score is more than 60.
- No cytapheresis and cell separation contraindication.
- Hemoglobin is more than 80 gram per litre.
- The function of important organ was satisfied:(1)cardiac ultrasound indicated that cardiac ejection fractions is more than 50%(EF≥50%), and the electrocardiogram showed no obvious abnormality;(2)Blood oxygen saturation is more than 90%(SpO2≥90%);(3)Creatinine(Cr) is less than 2.5 times normal range;(4)Alanine transaminase(ALT) and glutamic-oxalacetic transaminase(AST)is less than 3 times normal range,and total bilirubin is less than 2 milligram per deciliter(TBil≤2.0mg/dL).
- After discussion by the expert group, the patient's condition was analyzed and combined with the general physical condition of the patient, the benefit of participating in the clinical trial was greater than the risk.
- Volunteered for this clinical trail and signed a consent form .
Exclusion Criteria:
- Patients with high tumor burden or progression of disease need to control the progression of disease in order to decrease the tumor burden.
- Patients with active infection and fever.
- Patients' neutrophilic granulocyte has decreased more than 10 days,and is difficult to control after treatment.
- Patients are infected with fungus,bacteria or virus,and are difficult to control after treatment.
- Patients with infection of HIV or with actively infection of Hepatitis B Virus(HBV) or Hepatitis C Virus(HCV).
- Pregnant or lactating women.
- Patients with severe insufficient cardiac, pulmonary and hepatorenal functions.
- Patients had been treated with cell therapy but was invalid.After analyzing the patient's condition , the expert group think that the patient doesn't fit to attend the therapy of CART.
- The monoclonal antibodies of BCMA or CD38 are invalid for the patients who have used the drug.
- Any situation may do harm to the subjects or interfere the results.
- After allogeneic transplantation, patients are more than 3 degrees of acute Graft-Versus-Host disease(GVHD).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CART therapy in multiple myeloma
In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
|
one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events that Are related to treatment
Time Frame: 2 years
|
Determine the toxicity profile of the BCMA/CD138/CD38/CD56-targeted CAR-T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimate 2 year overall survival(OS) after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment
Time Frame: 2 years
|
To estimate 2 year overall survival(OS) after BCMA/CD138/CD38/CD56-CART infusion and sequential treatment with Relapsed/Refractory MM
|
2 years
|
Estimate 2 year relapse rate after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment
Time Frame: 2 years
|
To estimate 2 year relapse rate after BCMA/CD138/CD38/CD56-CART infusion and sequential treatment with Relapsed/Refractory MM
|
2 years
|
Estimate 2 year progression free survival after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment
Time Frame: 2 years
|
To estimate 2 year progression free survival after BCMA/CD138/CD38/CD56-CART infusion and sequential treatment with Relapsed/Refractory MM
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yanjie He, Zhujiang Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
Other Study ID Numbers
- 2017-XYNK-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed/Refractory Multiple Myeloma(MM)
-
Mario BoccadoroActive, not recruiting
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
Carl Ola Landgren, MD, PhDBristol-Myers SquibbRecruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
AmgenCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaCanada, Belgium, Spain, United States, Korea, Republic of, Australia, Czechia, Taiwan, Hungary, Austria, Romania, Japan, United Kingdom, Greece, Turkey, Bulgaria, France, Russian Federation, Poland
-
Regeneron PharmaceuticalsActive, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; H. Lee Moffitt...CompletedMultiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
Ionis Pharmaceuticals, Inc.Active, not recruitingRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States
-
TakedaCompletedRefractory Multiple Myeloma | Relapsed Multiple MyelomaUnited States, Canada
Clinical Trials on CART therapy in Relapsed/Refractory multiple myeloma
-
The Sixth Affiliated Hospital of Wenzhou Medical...Zhejiang Qixin BiotechUnknown
-
Centre Hospitalier Universitaire, AmiensWithdrawn
-
Nantes University HospitalTerminatedMultiple Myeloma in Older PatientsFrance
-
Second Affiliated Hospital of Wenzhou Medical UniversityCompleted
-
Zhujiang HospitalNanfang Hospital of Southern Medical University; The Third Affiliated Hospital... and other collaboratorsTerminatedRelapsed/Refractory Acute Myeloid Leukemia(AML)China
-
Memorial Sloan Kettering Cancer CenterRecruitingMultiple MyelomaUnited States
-
Marmara UniversityUnknown
-
Cystetic Medicines, Inc.DevPro BiopharmaRecruitingCystic FibrosisAustralia, New Zealand
-
Southern Methodist UniversityBoston University; University of MichiganCompletedPanic Disorder With AgoraphobiaUnited States
-
University of Turin, ItalyActive, not recruitingMultiple MyelomaItaly